Axsome In-Licenses Pfizer’s Reboxetine and Esreboxetine in the US

 Axsome In-Licenses Pfizer’s Reboxetine and Esreboxetine in the US

Axsome In-Licenses Pfizer’s Reboxetine and Esreboxetine in the US

Shots:

  • Pfizer to receive Axsome’s common shares of ~$8M, $3M in cash as upfront, ~$323M regulatory & commercial milestones and royalties in sales of the therapies and has right of first negotiation on any potential strategic transactions involving AXS-12 and AXS-14
  • Axsome to receive an exclusive license to Pfizer’s clinical, nonclinical data and intellectual property for AXS-12 (reboxetine) and an exclusive right to develop & commercialize AXS-14 (esreboxetine) in the US
  • AXS-12 is a highly selective and potent norepinephrine reuptake inhibitor, being evaluated in P-II study for narcolepsy with anticipated initiation of P-III study in 2020 while AXS-14 is SS-enantiomer of reboxetine which met its 1EPs in P-III & P-II study for the treatment of fibromyalgia

Click here to­ read full press release/ article | Ref: GlobeNewswire | Image: Axsome

Tuba Khan

Tuba Khan is an Editor and Digital Marketing expert at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in Lifesciences industry. She covers Pharma, Medical devices, Diagnostics and Digital health segment. Tuba also has an experience of digital and social media marketing and can run the campaign independently. She is also certified as a Digital marketer and social media marketer. She can be contacted on tuba@pharmashots.com

Related post